| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.48 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Introduction and aims: The introduction of recombinant human erythropoietin (rHuEpo) improved the treatment of anemia in chronic kidney disease patients. However, in the recent years, some concerns were raised about this therapy, namely the development of cardiovascular complications, one of the major causes of death in the patients. Hypertention development is closely associated with renal deterioration and is one of the most described side effects associated with rHuEpo therapy. The aim of this study was to assess the effect of rHuEpo-induced hypertension on renal function and lesions, using an animal model.
Descrição
Palavras-chave
anemia recombinant human erythropoietin (rHuEpo) chronic kidney disease
Contexto Educativo
Citação
Sandra Ribeiro, João Fernandes, Patrícia Garrido, José Sereno, Helena Vala, Elsa Bronze da Rocha, Luís Belo, Elísio Costa, Flávio Reis and Alice Santos-Silva (2014). Rhuepo induced-hypertension leads to early renal damage. Nephrol. Dial. Transplant, 29 (suppl 3): iii79-iii89